We've made it easier for you to connect! Fill out your NEW profile.

FDA Approves Orserdu for ER+ MBC (oral SERD)

moderators
moderators Posts: 9,078
edited February 2023 in Stage IV/Metastatic Breast Cancer, Open to All To Contribute

FDA Approves Orserdu for Metastatic, Estrogen Receptor-Positive Breast Cancer
Jan 27, 2023
The FDA has approved Orserdu, a new oral medicine to treat metastatic, estrogen receptor-positive, HER2-negative breast cancer with an ESR1 mutation. Read more....

Categories

Join Us on Zoom: Upcoming virtual support groups. Read more...
Share more about you! Fill out your NEW profile.